Drug Development, Not Conflicts, Dominates Gottlieb's Confirmation Hearing
The most questions were asked about issues such as accelerated approval and clinical trials, not Gottlieb's ties to industry.
You may also be interested in...
A plurality of the questions from the Senate HELP Committee at Stephen Hahn's confirmation hearing to head the US FDA focused on drug development issues, despite the time lawmakers spent discussing the agency's regulation of e-cigarettes.
US FDA commissioner nominee could face a slew of questions about non-drug issues such as e-cigarette regulation, which may mean pharma must read between the lines for insight into his drug-related policy stances.
Nominee for US FDA commissioner has remained largely focused on academic work and private practice, receiving only a few payments from pharma and device companies.